In the new US patent with over 100 compounds and targeting iron, the main indication the company wants to mention after positive preclinical testing is dementia: "at least one of which has demonstrated efficacy in an animal model of dementia". There are many different diseases under the term dementia: vascular dementia, Alzheimer's, Lewy bodies, PD, frontotemporal, alcoholism, etc. Looks like they will perhaps start with AD as it is the biggest part of dementia patients with almost 6M in the USA and it looks like iron has a role in its pathogenesis. Stamler told that "we will continue to look to expand our pipeline with new, patentable compounds that may modify the course of disease.” This may be related that there could soon be a new product in the pipeline. Perhaps competitors are also coming to this field as an expedited review process was used in the US patent application.
Now that the patent has been granted, I would think that we will see some results of the preclinical studies.
ATH Price at posting:
1.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)